LABORATORY NEWS
-
YD Bio And EG BioMed Expand U.S. Access To OkaiDx™, A cfDNA Methylation Blood Test For Post Treatment Breast Cancer Monitoring
YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx™, a research‑use‑only (RUO) blood test for post‑treatment breast cancer monitoring now available through the Company’s affiliate EG Biomed US Inc.
- Illumina And Grail Veterans Launch Hepta With First Liquid Biopsy-Native AI That Detects Liver Disease With Tissue-Level Biological Insights
- QIAGEN To Acquire Parse Biosciences, Expanding Its Sample Technologies Portfolio Into Highly Scalable Single-Cell Solutions
- Countable Labs Announces Additional Modules For Countable PCR Expanding Its Utility For Translational Research, Cell And Gene Therapy Manufacturing, And Diagnostic Development
- SimplyTest Partners With Evexia Diagnostics To Expand Access To PERIO And 4-Point Cortisol Tests For Functional And Integrative Health Practitioners
ARCHIVED NEWSLETTER
- 11.11.25 -- Risk-Based Analytical Method Selection In Cleaning Validation Using ASTM International Standards
- 10.21.25 -- Automation In The Lab: Lessons From Successes And Setbacks
- 10.07.25 -- Unpacking Pfizer's Advanced Process Control Platform For Upstream Ops
- 09.23.25 -- Weight Of Evidence Assessments For Carcinogenicity Studies: An Overview
- 09.09.25 -- Nearly 40% Of Biomanufacturers Eyeing Continuous Processing